Redox-active Microcapsules as Drug Delivery System in Breast Cancer Cells and Spheroids

Marisa Colone 1, Subramanian Kaliappan 2, Annarica Calcabrini 3, Mariarosaria Tortora 4, Francesca Cavalieri 5 and Annarita Stringaro 1*

1 Department of Technology and Health, Istituto Superiore di Sanità, 00161 Rome, Italy
2 Department of Chemical Science and Technology, University of Tor Vergata, 00133 Rome, Italy
3 Corresponding author: Annarita Stringaro, Department of Technology and Health, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy, Tel: 39064902917, Fax: 39064902137; E-mail: annarita.stringaro@iss.it

Received date: October 15, 2015; Accepted date: January 20, 2016; Published date: January 27, 2016

Abstract

The purpose of our study was to develop new delivery systems for drugs effective against breast cancer by using biodegradable and biocompatible capsules. Redox-active microcapsules based on thiolated polymethacrylic acid (PMA) were employed. The interaction of these PMA SH capsules with breast cancer cells and the mechanism of their internalization was investigated. PMA SH biocompatibility was evaluated by MTT assay. To analyze their potential as drug carrier, we incorporated doxorubicin into the capsules. Confocal microscopy observations showed the presence of capsules inside the cells. Although some drug molecules still appeared co-localized with PMA SH capsules, strong doxorubicin fluorescence was observed both in the cytoplasm and nucleus, indicating the disassembling of the capsule into PMA SH-drug conjugate after internalization. These results were confirmed by both flow cytometry (time course of capsule uptake) and scanning electron microscopy. PMA SH capsules were also internalized in 3D cell structures (spheroids) suggesting their potential use as drug delivery system for treatment of human diseases.

Keywords: Breast cancer; Spheroids; PMA SH capsules; Drug delivery; Scanning electron microscopy; Confocal microscopy

Abbreviations

CLSM: Confocal Laser Scanning Microscopy; DOX: Doxorubicin; ECM: Extracellular Matrix; GSH: Glutathione; HBSS: ice-cold Hank’s Balanced Salt Solution; MCB: Monochlorobimane; MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; PBS: Phosphate Buffer Saline; PMA SH: Thiolated Poly (methacrylic acid) Capsules; SEM: Scanning Electron Microscopy

Introduction

Breast cancer is the most frequent type of malignancy and the leading cause of cancer deaths of women in developed countries; it constitutes 23% of total cancer cases and 14% of the cancer deaths [1]. Approximately up to 7% of breast cancers are being diagnosed in women less than 40 years old years and less than 4% in women below the age of 35 years [2]. Breast cancer is a heterogeneous disease that can be classified into several subtypes, having different histological, molecular expression signature and clinical outcomes [3].

Hormonal therapy, surgery, radiation and chemotherapy represent the treatment options for breast cancer patients. Chemotherapeutic agents currently approved for breast cancer treatment include several drugs (anthracyclines, alkylating agents, platinum drugs, taxanes, vinca alkaloids) (NIH, National Cancer Institute, http://www.cancer.gov/about-cancer/treatment/drugs/breast). Unfortunately, they often show lack of selectivity or specificity toward cancer cells, resulting in several side effects [4].

Recently, nanomedicine has received increasing attention for its ability to improve the efficacy of cancer therapeutics. Nanosized polymer therapeutic agents offer the advantage of prolonged circulation in the blood stream, targeting to specific sites, improved efficacy and reduced side effects. Various drug delivery systems such as nano/microparticles, liposomes and implants have been demonstrated to significantly enhance the preventive/therapeutic efficacy of many drugs by increasing their bioavailability and targetability. Furthermore, their administration would become less expensive in the near future [5]. The achievement of a local, controlled delivery of the drug at the target site would allow keeping the systemic concentration of the drug low. In this regard, other Authors reported that “ideal smart nanoparticles” for redox and pH-responsive drug delivery system (DDS) should enhance therapeutic efficacy thus reducing side effects due to bioaccumulation [6,7].

The purpose of our study was to verify a drug delivery system for breast cancer cells using a microcarrier for doxorubicin (DOX) which disassembles into a polymer-DOX conjugate after internalization. To this aim, we decided to use redox sensitive degradable microcapsules. It is well known that in tumor tissues and in cancer cell cytosol, biological reducing agents have a 4-fold higher concentration than that in the normal tissues [8]. Based on this finding, redox shell-shedding capsules possess great prospective for anticancer drug release because they are stable in the extracellular environment but able to rapidly respond to the intracellular GSH, releasing drugs into the cytosol and nuclei.

Redox-active microcapsules based on thiolated poly (methacrylic acid) (PMA SH) have been extensively studied over the past few years. PMA SH are assembled by the alternate deposition of PMA SH and poly(vinylpyrrolidone) (PVPON) onto silica particles, followed by subsequent cross-linking of the thiol groups in the PMA SH to form stable disulfide bonds and dissolution of the sacrificial silica core. The disulfide-bonded capsules are designed to be stable in oxidizing
conditions (such as the bloodstream) but to disassemble in reducing environments such as the cytoplasm of the cell [9-12]. The potential of PMA\textsubscript{SH} as an \textit{in vitro} therapeutic delivery system of encapsulated proteins and peptides, oligonucleotides as well as small molecule drugs, has been demonstrated [13,14]. Previous studies reported the cytotoxic effect induced in human colorectal cells by DOX loaded into PMA\textsubscript{SH} capsules by an oil phase or by pH labile hydrazone linkages [9,15]. Herein we report the loading of PMA\textsubscript{SH} microcapsules with DOX using no hydrolysable amide bonds. The interaction of these PMA\textsubscript{SH} capsules with a cancer cell model (SKBR3, human breast cancer cell line) as well as the mechanism of their internalization were then investigated. In addition, in order to predict more accurately \textit{in vivo} results, PMA\textsubscript{SH} capsules were assessed as delivery system in SKBR3 cells grown as spheroids in 3D culture model to analyse their efficacy in a system that mimics \textit{in vivo} condition.

Materials and methods

Cell culture

The human breast cancer cell line SKBR3 was from American Type Culture Collection (ATCC, Rockville, MD). Cells were grown in DMEM (EuroClone S.p.A., Milan, Italy) supplemented with 10% FBS at 37°C in a humidified atmosphere containing 5% CO\textsubscript{2} and sub-cultured prior to confluence using trypsin/EDTA.

Three-dimensional (3D) cell culture

SKBR3 cells were also cultured as multicellular spheroids. To this aim, 3D ON-TOP assay was performed [16]. Eight-well glass chamber slides were pre-coated with undiluted growth factor-reduced Matrigel\textsuperscript{TM} (10 mg/ml) (BD Biosciences, Franklin Lakes, NJ, USA). After Matrigel solidification, 3 x 10\textsuperscript{3} SKBR3 cells (resuspended in 100 µl growth medium) were seeded on each well and incubated for 10-30 min at 37°C. A mixture of complete medium containing 10% Matrigel was added to the plated culture (100 µl/well). Cultures were maintained for 12-15 days, replacing Matrigel-medium mixture every 2 days. To analyse the effects of DOX-loaded PMA\textsubscript{SH} once spheroids were formed (10 days), the particles (1:25) were added to this mixture (3D cultures) and their effects analysed after 72 h.

Preparation of PMA\textsubscript{SH} microcapsules and PMA\textsubscript{SH} capsules loaded with doxorubicin

PMA\textsubscript{SH} and PMA\textsubscript{SH} capsules, 1 µm in diameter, were prepared as previously reported [17]. DOX was covalently linked with the carboxyl group of PMA\textsubscript{SH} capsules using EDC chemistry procedure. The carboxyl groups were activated when 100 µl PMA\textsubscript{SH} capsules were incubated with 0.010 mg of EDC (5.3 x 10\textsuperscript{5} mmol) at pH 7 in PBS (phosphate buffer saline) for 30 minutes. Subsequently the capsules were incubated with DOX (5.3 x 10\textsuperscript{5} mmol) for 30 minutes at pH 7 in PBS buffer and washed to remove free drug. The concentration of (PMA\textsubscript{SH}) microcapsules was determined by using a counting chamber: 0.5 µl of PMA\textsubscript{SH} capsules were diluted 10 times with PBS buffer at pH 7 and 1 µl of the diluted PMA\textsubscript{SH} capsules was placed on a glass slide. Then, capsules were counted from the micrographs obtained by optical microscopy.

Determination of DOX loaded into PMA\textsubscript{SH} capsules

The amount of DOX loaded into PMA\textsubscript{SH} capsules was determined using UV spectroscopy. At first, the concentration of DOX in the medium (initial concentration) was measured. After loading, the PMA\textsubscript{SH} capsules were centrifuged and the absorbance of DOX present in the supernatant was measured. The amount of doxorubicin loaded into PMA\textsubscript{SH} capsules was calculated using the formula: % uptake=Initial DOX Concentration – Concentration of free DOX in the supernatant (after reaction)/ Initial DOX Concentration. Doxorubicin loaded onto PMA\textsubscript{SH} microcapsules was also quantified after microcapsule disassembly. As DOX is covalently bonded with the carboxylic group of microcapsules by amide linkage and the amide linkage is not hydrolyzed, doxorubicin release was performed in the presence of the reducing agent DTT. Under this condition, dissolution of microcapsules caused PMA\textsubscript{SH}-DOX release. In brief, 50 mM of freshly DTT in PBS buffer (pH 7) was added to DOX loaded capsules. Subsequently the capsules were centrifuged at 4.5 rcf for 10 minutes. The absorbance of the supernatant was measured by UV spectroscopy. From the absorbance value the amount of DOX released was calculated. The loading of drug into the microcapsule suspension was 3.4 x 10\textsuperscript{-10} mg of DOX per microcapsule.

MTT assay

Briefly, SKBR3 cells were seeded into 96-well microtiter plates (NunclonTM, Nunc, Germany) at a density of 1.5 x 10\textsuperscript{4} cells/well. After 24 h cells were treated with polymer, empty PMA\textsubscript{SH} and PMA\textsubscript{SH} loaded with DOX at concentration of 25, 50, 75 or 100 particles/cell. After an incubation period of 24, 48, 72 h, medium was replaced by fresh medium containing 0.5 mg/ml MTT (Sigma, Deisenhofen, Germany). After 2 h at 37°C, unreacted dye was removed and the purple formazan product was dissolved in 200 µl/well dimethylsulfoxide (Merck, Darmstadt, Germany). The absorbance was read at 570 nm on a scanning microtiter spectrophotometer after agitating the plate for 5 min on a shaker. Data were expressed as absorbance values relative to untreated cells considered as 100%. Assays were performed in triplicate and repeated 2-3 times [18].

Scanning electron microscopy

The effects of PMA\textsubscript{SH} on cell morphology were visualized by scanning electron microscopy (SEM). Cells were grown on glass coverslips (12 mm-diameter) and treated with particles for 24 and 48 h (1:25). After incubation, samples were washed to remove unbound PMA\textsubscript{SH} and fixed in 2.5% glutaraldehyde in 0.2 M Na-cacodylate buffer (pH 7.4) for 2 h at RT. After 3 washes, cells were post-fixed with 1% (w/v) OsO\textsubscript{4} for 1 h, dehydrated in an ethanol gradient, critical point dried in CO\textsubscript{2}. The coverslips were attached to aluminium stubs, mounted with silver print and coated with gold in a sputter coater. The samples were examined with a Cambridge Stereoscan 360 scanning electron microscope (Cambridge Instruments, Cambridge, UK).

Flow cytometry

To quantitatively analyse intracellular uptake of doxorubicin-loaded PMA\textsubscript{SH} capsules, SKBR3 cells (5 x 10\textsuperscript{3} cells/well) were seeded in 6-well plates and incubated at 37°C in a 5% CO\textsubscript{2} incubator overnight. DOX-loaded PMA\textsubscript{SH} capsules were added to the culture medium at the final concentrations of 1.25 cell/DOX-particles at 37°C from 24 h to 48 h. At the end of each treatment, cells were washed with ice-cold Hank’s balanced salt solution (HBSS; Sigma Chemical Company, St. Louis,
MO, USA), detached with EDTA and 0.25% trypsin, resuspended in ice-cold PBS and immediately examined for a time course analysis of the uptake by LRSII flow cytometer (Becton Dickinson and Company, Franklin Lakes, NJ, USA). Moreover, to determine cellular glutathione (GSH) content, SKBR3 cells (3×10^5 cells/well) were seeded in 6-well plates and incubated at 37°C in a 5% CO2 incubator overnight. GSH level was quantified using monochlorobimane (MCB, Molecular Probes, Eugene, OR, USA), a non-fluorescent compound that reacts with GSH to form a highly fluorescent derivative. Cells were treated with DOX-PMAS_{SH} at 1:25 cell/capsules, at 37°C from 24 h to 72 h, then incubated with MCB solution (25 μg/ml) for 15 min at 37°C. Samples were washed with HBSS and detached as described above, then analyzed by flow cytometry. Fluorescence emissions from DOX-loaded capsules and from MCB were collected through a 570 and 530 nm band-pass filter, respectively, and acquired in log mode.

Confocal laser scanning microscopy

The analysis of the internalization process of DOX-loaded PMAS_{SH} capsules was performed by confocal laser scanning microscopy (CLSM) on both cell cultures and multicellular spheroids. SKBR3 cells were grown on coverslips and treated with capsules (1:25) for 24, 48, 72 h. 3D cultures grown for 10 days, as previously described, were treated for 72 h with PMAS_{SH} at the same concentration. Subsequently, monolayer cultures and spheroids were fixed with 4% paraformaldehyde in PBS (pH 7.4) for 30 min at room temperature (RT), washed in the same buffer and permeabilized with 0.5% Triton X-100 (Sigma Chemicals Co.) in PBS (5 min for cells, 20 min for spheroids) at RT. For nuclei detection, cells and spheroids were stained with DAPI (150 nM Sigma) at 37°C for 30 min.

For Golgi apparatus detection, cells were incubated with IgG1 monoclonal antibody (Purified Mouse Anti-GM130, diluted 1:100, BD Transduction Laboratories Inc.,) at RT, followed by detection with Alexa Fluor 488-labeled goat anti-mouse IgG for 1 h at RT. After washing with PBS, coverslips were mounted with glycerol-PBS (2:1) and analyzed by intensified charge-coupled device video microscopy (IVM) with a Nikon Microphot fluorescence microscope (Nikon Europe B.V., Amsterdam, The Netherlands) equipped with a Zeiss CCD camera (Carl Zeiss, Oberkochen, Germany). Confocal microscopy experiments were performed on a Olympus IX81 confocal laser scanning microscope (Olympus, Tokyo, Japan) equipped with Ar laser 488 nm.

Statistical analysis

One-way ANOVA test was used to perform statistical analysis of the data. Differences between two groups were considered significant at p<0.05.

Results and Discussion

To evaluate the potential use of PMAS_{SH}-DOX capsules as an in vitro delivery system for breast cancer cells, the effect of thiolated polymethacrylic acid) and PMAS_{SH} capsules on cell growth and viability was analyzed by MTT assay. This test is based on the reduction ability of tetrazolium salts to formazan by metabolically active cells, which correlates with the number of viable cells. As shown in Figure 1A, cell viability was not affected after incubation with different polymer solutions at increasing concentration (0.001, 0.01 and 0.1 mg/ml). Only after 72 h of treatment with 0.1 mg/ml the polymer induced a low cytotoxic effect. Furthermore, treatments with PMAS_{SH} capsules (25, 50, 75 and 100 PMAS_{SH} capsules/cell ratio) up to 72 h of incubation did not alter substantially the number of viable cells (Figure 1B). On the basis of this evidence, in the studied concentration range, both polymer and PMAS_{SH} capsules resulted to be not toxic for SKBR3 cells.

In order to evaluate the potential of PMAS_{SH} capsules as a carrier to deliver anticancer drugs, DOX was covalently linked into the capsules. DOX has an intrinsic fluorescence (excitation at 480 nm, emission at 550-650 nm) that can be exploited to monitor the intracellular accumulation of the drug. SKBR3 cells were treated with different capsules/cell ratios (Figure 1C). The effect induced by these particles was time- and dose-dependent: an evident reduction of viable cell number was observed after incubation for 72 h with all tested capsules/cell ratios (1:50, 1:75, 1:100). These studies indicated 25 capsules/cell as an optimal ratio to study the efficiency and the kinetics of the uptake. Next, SKBR3 cells were incubated with PMAS_{SH}-DOX at the same capsules/cell ratio, washed and analysed by flow cytometry.

The increase of DOX-related fluorescence signal was detected as a function of time. Figure 2 shows that the cellular uptake process of PMAS_{SH}-DOX capsules was already complete after 48 h incubation as the fluorescent signal did not change at longer incubation times (data not shown).

Scanning electron microscopy (SEM) was used to gain an understanding of the mechanism of interaction between cells and capsules during the uptake process. SEM micrographs revealed the adhesion of PMAS_{SH}-DOX capsules on cell surface. Some PMAS_{SH}-DOX particles could be observed on cell membranes after 24 h incubation (Figure 3A, arrows). After 48 h, numerous membrane protrusions and ruffles could be observed on cell surface (Figure 3B, arrow) suggesting that the internalization process (Figure 3C, arrow) might involve these structures related to cell cytoskeleton. No evidence of cell damage could be detected after 48 h of incubation (Figure 3B and 3C). In
Figure 3D (72 h of incubation) arrows indicate the PMA$_{SH}$-DOX capsules inside the cytoplasm underlying the plasma membrane as demonstration of capsules uptake.

**Figure 2:** Flow cytometric study of the uptake process of DOX-loaded PMA$_{SH}$ capsules by SKBR3 cells. After 24 and 48 h incubation, fluorescence signals arising from capsules that entered the cells were analyzed and represented as mean fluorescence channel. Data show the mean value ± the standard deviation of three independent experiments (k, untreated cells).

**Figure 3:** SEM images of SKBR3 cells treated for 24 h (A), 48 h (B and C) and 72 h (D) with PMA$_{SH}$-DOX at 1:25 ratio.

Further insight into the internalization and intracellular distribution of PMA$_{SH}$-DOX capsules was gained by CLSM observations (Figure 4) after an incubation period of 48 h. Red, green and blue colours indicate PMA$_{SH}$-DOX, actin filaments and nuclei stained with Hoechst 33342, respectively. The arrows in the micrographs indicate the internalization of PMA$_{SH}$-DOX capsules and the localization of DOX inside the nucleus after microcapsules disassembling (Figures 4A and 4B, respectively). These observations suggested that PMA$_{SH}$-DOX conjugate was able to migrate into the nucleus crossing the nuclear membranes. In order to investigate if other cellular compartments could represent localization sites for PMA$_{SH}$-DOX capsules, Golgi apparatus was stained with the monoclonal antibody anti-GM130. After 48 h incubation with PMA$_{SH}$-DOX capsules, shift was observed after intact capsules near Golgi apparatus (Figure 4C, arrows). However, some SKBR3 cells showed evidence of yellow merged fluorescence signal arising from DOX conjugate polymer co-localized near the nucleus, in Golgi area (Figure 4C, inset). Other studies reported that free doxorubicin shows a time-dependent intracellular shift from the nucleus to the mitochondria and Golgi apparatus [19]. In particular, Golgi apparatus plays a pivotal role in the intracellular distribution of DOX [20]. These results indicate that other organelles in addition to nuclei are important sites of accumulation of PMA$_{SH}$-DOX polymer. In order to investigate intracellular PMA$_{SH}$-DOX capsule fate in suffering and/or dead SKBR3 cells after 72 h of incubation, detached cells were collected from the supernatant medium and placed on glass coverslips, previously covered with polylysine, then processed for CLSM analysis. The induction of apoptotic death by PMA$_{SH}$-DOX capsules was confirmed by the observation of nuclei with typical areas of condensed chromatin (Figure 4D). The inset shows a 3D reconstruction image of an apoptotic cell.

**Figure 4:** CLSM images of SKBR3 cells incubated with PMA$_{SH}$-DOX capsules. (A) SKBR3 cells at 48 h of incubation with capsules. (B) A three-dimensional CLSM reconstruction of the same samples (CLSM 3D mode image). (C) CLSM images of adherent SKBR3 cells after 48 h of incubation with PMA$_{SH}$-DOX. Golgi areas are green while PMA$_{SH}$-DOX capsules are red. Inset shows open PMA$_{SH}$-DOX capsules in Golgi area at 72 h of incubation (yellow signal from merged image). (D) Apoptotic SKBR3 cells present in the supernatant after 72 h of PMA$_{SH}$-DOX incubation. The inset shows a CLSM 3D mode image. Red, green and blue indicate PMA$_{SH}$-DOX, actin filaments and nuclei stained with Hoechst 33342, respectively.

As previously described, PMA$_{SH}$ capsules are assembled by subsequent cross-linking of the thiol groups [11]. The disulfide-bonded
capsules are stable in oxidizing conditions (such as the bloodstream) but disassemble in reducing environments such as the cytoplasm of the cell [21]. The intracellular reducing condition promotes PMA₅⁻DOX capsules dissolution into polymer-DOX soluble conjugate. As DOX is linked to PMA₅ polymer chains via amide linkages, the DOX intercalation into DNA grooves is likely sterically hindered by the polymer chain. We speculate that PMA₅-DOX caused anti-proliferative and cytotoxic effect in SKBR3 cells through different mechanisms including generation of free radicals and direct membrane alterations.

To demonstrate the intracellular redox-induced rupture of PMA₅⁻DOX capsules, we evaluated GSH cytoplasmatic concentration during PMA₅ capsules trafficking in SKBR3 cells. The modulation of GSH level during PMA₅-DOX particles uptake was evaluated by flow cytometry analysis after labelling of GSH with MCB (Figure 5). The lowest fluorescent signal, corresponding to a lowest concentration of GSH, was observed after 48 h incubation at the ratio 25 capsules/cell. This result suggested that the decrease of reduced GSH could be associated with the dissolution of PMA₅ particles and consequently with the release of PMA₅-DOX in the intracellular space. Evidence of PMA₅-DOX capsules dissolution was also provided by the homogeneously distributed red emission observed by CLSM analysis (Figure 4A, inset Figure 4D). From these observations we could hypothesize that PMA₅-DOX capsules exerted their apoptotic activity in SKBR3 cells within 48 h by disassembling into cytotoxic PMA₅-DOX polymer.

![Figure 5: Flow cytometric analysis of GSH levels by using MCB. SKBR3 cells were treated with PMA₅-DOX capsules for 24, 48 and 72 h. Fluorescence signals were represented as mean fluorescence channel. Data show the mean value ± the standard deviation of three independent experiments (k, untreated cells).](image)

To evaluate micro-nanocarriers biological efficacy, monolayer (2D) cell cultures are typically used as in vitro testing models. However, these studies often are unable to predict in vivo results. 2D-cultures do not reproduce the complex cell-cell and cell-matrix interactions, which significantly limit their ability to recapitulate the appropriate level of in vivo cellular response. In vitro 3D-culture models have been introduced to reduce the gap between in vitro 2D-cultures and in vivo models [22]. Multicellular spheroid is considered the most effective 3D cell culture model [23]; it is characterized by many features of in vivo condition such as the interaction of cells with the extracellular matrix (ECM) components [24]. To assess if 3D organization and ECM presence could affect the entry and interaction of PMA₅-DOX capsules with individual cells, SKBR3 cells were grown following a 3D-dimensional cell culture protocol that employs Matrigel [16]. SKBR3 spheroids appeared as multicellular aggregates characterized by poor cell-cell adhesion (Figures 6A and 6B, optical and scanning electron microscopy, respectively), as previously observed by other Authors [25]. To better analyse internal organization, spheroids were labelled with nuclear stain DAPI and observed by confocal microscopy (Figure 6C). To study the interaction with capsules, SKBR3 spheroids after 10 day-growth were treated for 72 h with PMA₅-DOX capsules (1:25) and observed by confocal microscopy (Figure 6D). PMA₅-DOX capsules and polymer were observed inside the 3D cultures (Figure 6D, arrow). In addition, some nuclei positive for DOX signal could be detected suggesting the presence of drug released from the opened capsules (Figure 6D, arrowhead). These results suggested that the presence of Matrigel (which mimics the ECM structure in in vivo growth condition) allowed the entry and diffusion of capsules inside the 3D organized structures.

![Figure 6: SKBR3 spheroid (10 day-growth) observation by phase-contrast optical (A) and scanning electron microscopy (B). CLSM image of control spheroids labelled with nuclear dye DAPI (C). CLSM micrograph of spheroids after 72h treatment with PMA₅⁻DOX capsules (D) showing both the presence of capsules near the nuclei (arrow) and some drug-positive nuclei (arrowhead).](image)

**Conclusion**

We showed that PMA₅-DOX capsules exhibited an efficient intracellular controlled release of PMA₅-DOX conjugate in breast cancer cells and spheroids. In vitro cell viability assay indicated that PMA₅-DOX capsules could efficiently inhibit SKBR3 cell viability at long incubation times, suggesting that the antitumoral drug maintained its activity even if conjugated to a polymer by a non-hydrolyzable linkage. Cellular uptake studies showed that PMA₅-DOX conjugate was able to access the nuclei of SKBR3 cells, following PMA₅-DOX capsules dissolution induced by intracellular reducing condition. Results obtained in SKBR3 cells grown as spheroids...
indicated that PMA\textsubscript{SH} capsules were also able to enter and move into these 3D organized cellular structures suggesting that PMA\textsubscript{SH} capsules could represent a promising vehicle for intracellular controlled drug delivery in nanomedicine.

References

1. DeSantis C, Ma J, Bryan L, Jemal A (2014) Breast cancer statistics, 2013. CA Cancer J Clin 64: 52-62.
2. Brinton LA, Sherman ME, Carreon JD, Anderson WF (2008) Recent trends in breast cancer among younger women in the United States. J Natl Cancer Inst 100: 1643-1648.
3. Sorial T, Tibshirani R, Parker J, Hastie T, Marron SJ et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100: 8418-8423.
4. Hassan MU, Ansari J, Spooner D, Hussain SA (2010) Chemotherapy for breast cancer. Oncol Reports 24: 1121-1131.
5. Misra R, Acharya S, Sahoo SK (2010) Cancer nanotechnology: application of nanotechnology in cancer therapy. Drug Discov Today 15: 842-850.
6. Bahadur KCR, Chandrashekar V, Cheng B, Chen H, et al. (2014) Redox potential ultrasensitive nanoparticle for the targeted delivery of camptothecin to HER2-positive cancer cells. Mol Pharm 11: 1897-1905.
7. Vivek R, Thangam R, Nipunbabu V, Ponraj T, Kannan S, et al. (2014) Oxaliplatin-chitosan nanoparticles induced intrinsic apoptotic signaling pathway: a ‘smart’ drug delivery system to breast cancer cell therapy. Int J Biol Macromol 65: 289-297.
8. Meng F, Cheng R, Deng C, Zhong Z (2012) Intracellular drug release nanosystems. Mater Today 15: 436-442.
9. Yan Y, Such GK, Johnston APR, Lomas H, Caruso F (2011) Toward therapeutic delivery with layer-by-layer engineered particles. ACS Nano 5: 4252-4257.
10. Yan Y, Wang Y, Heath JK, Nice EC, Caruso F (2011) Cellular association and cargo release of disulfide-responsive polymer capsules mediated by exofacial thiols. Adv Mater 23: 3916-3921.
11. Yan Y, Johnston AP, Doods SJ, Kamphuis MM, Ferguson C, et al. (2010) Uptake and intracellular fate of disulfide-bonded polymer hydrogel capsules for Doxorubicin delivery to colorectal cancer cells. ACS Nano 4: 2928-2936.
12. De Koker S, Hoogenboom R, De Geest BG (2012) Polymeric multilayer capsules for drug delivery. Chem Soc Rev 41: 2867-2884.
13. Becker AL, Orlotti NI, Folini M, Cavalieri F, Zelikin AN, et al. (2011) Redox-active polymer microcapsules for the delivery of a survivin-specific siRNA in prostate cancer cells. ACS Nano 5: 1335-1344.
14. Beretta GL, Folini M, Cavalieri F, Yan Y, Frensch E, et al. (2015) Unravelling ‘off-target’ effects of redox-active polymers and polymer multilayered capsules in prostate cancer cells. Nanoscale 7: 6261-6270.
15. Cui J, Yan Y, Wang Y, Caruso F (2012) Templated assembly of pH-labile polymer–drug particles for intracellular drug delivery. Adv Funct Mater 22: 4718-4723.
16. Lee GY, Kenny PA, Lee EH, Bissell MJ (2007) Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods 4: 359-365.
17. Zelikin AN, Quinn JF, Caruso F (2006) Disulfide cross-linked polymer capsules: en route to biodeconstructable systems. Biomacromolecules 7: 27-30.
18. Cavalieri F, Colone M, Stringaro A, Tortora M, Calcabrini A, et al. (2013) Influence of the morphology of lysozyme-shelled microparticles on the cellular association, uptake, and degradation in human breast adenocarcinoma cells. Part Part Syst Char 8: 695-705.
19. Beyer U, Rothern-Rutishauser B, Unger C, Wunderli-Allenspach H, Kratz F (2001) Differences in the intracellular distribution of acid-sensitive doxorubicin-protein conjugates in comparison to free and liposomal formulated doxorubicin as shown by confocal microscopy. Pharm Res 18: 29-38.
20. Arancia G, Calcabrini A, Meschini S, Molinari A (1998) Intracellular distribution of anthracyclines in drug resistant cells. Cytotechnology 27: 95-111.
21. Wang D, Xu Z, Chen Z, Liu X, Hou C, et al. (2014) Fabrication of single-hole glutathione-responsive degradable hollow silica nanoparticles for drug delivery. ACS Appl Mater Interfaces 6: 12600-12608.
22. Yamada KM, Cukierman E (2007) Modeling tissue morphogenesis and cancer in 3D. Cell 130: 601-610.
23. Small PS, Lioni M, Herlyn M (2006) Life isn’t flat: taking cancer biology to the next dimension. In Vitro Cell Dev Biol Anim 42: 242-247.
24. Goodman TT, Ng CP, Pun SH (2008) 3-D tissue culture systems for the evaluation and optimization of nanoparticle-based drug carriers. Bioconjug Chem 19: 1951-1959.
25. Kenny PA, Lee GY, Myers CA, Neve RM, Semelks JR, et al. (2007) The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol 1: 84-96.
Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:
Colone, M; Kaliappan, S; Calcabrini, A; Tortora, M; Cavalieri, F; Stringaro, A

Title:
Redox-active Microcapsules as Drug Delivery System in Breast Cancer Cells and Spheroids

Date:
2016

Citation:
Colone, M; Kaliappan, S; Calcabrini, A; Tortora, M; Cavalieri, F; Stringaro, A, Redox-active Microcapsules as Drug Delivery System in Breast Cancer Cells and Spheroids, Journal of Molecular and Genetic Medicine, 2016, 10 (01)

Persistent Link:
http://hdl.handle.net/11343/127925

File Description:
Published version